Sodium-glucose cotransporter 2 inhibition through henagliflozin ameliorates cognitive impairment in patients with type 2 diabetes.
Shujun ZhangFen WangLei XieJialu XuXiaoqing SongJing TaoJuan ChenDelin MaXue-Feng YuXiaoli ShiYan YangPublished in: Journal of diabetes investigation (2024)
Henagliflozin treatment was independently associated with improvements in Montreal Cognitive Assessment scores and plasma phosphorylated tau181 levels, indicating significant beneficial effects on cognitive impairment in patients with type 2 diabetes.